Biopharma Daily Stock Updates - 01/29/21

$XBI $152.88 (+0.82%) 📈

COVID:

$CYDY (+8.82%) - Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyn’s Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP Use

$AZN (-2.77%) - COVID-19 Vaccine AstraZeneca authorized for use in the EU

$BNTX (+6.31%) & $PFE (+0.14%) - Pfizer and BioNTech Publish Data on COVID-19 Vaccine-Induced Antibodies’ Ability to Neutralize SARS-CoV-2 U.K. Strain Pseudovirus in Cell Culture in Science

$HGEN (-1.97%) - Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19

$RDHL (-4.54%) - RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib

PIPELINE:

$AMRN (+2.74%) - AMARIN RECEIVES POSITIVE CHMP OPINION FOR ICOSAPENT ETHYL FOR CARDIOVASCULAR RISK REDUCTION

$KPTI (+1.53%) - Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

$PBYI (-0.35%) - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020

$AZN (-2.77%) - Datopotamab deruxtecan and Enhertu show promising early clinical activity in patients with advanced non-small cell lung cancer

$AZN (-2.77%) - Tagrisso extended disease-free survival regardless of prior adjuvant chemotherapy in early-stage EGFR-mutated lung cancer

FINANCIAL:

$CBIO (-1.40%) - Catalyst Biosciences Announces Closing of Public Offering of Common Stock

$RIGL (+4.60%) - Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients

$OTLK (-23.35%) - Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million